Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. 2003

Reginald V N Lord, and Ji Min Park, and Kumari Wickramasinghe, and Steven R DeMeester, and Stefan Oberg, and Dennis Salonga, and Jon Singer, and Jeffrey H Peters, and Kathleen D Danenberg, and Tom R Demeester, and Peter V Danenberg
Department of Surgery and Cardiothoracic Surgery, University of Southern California Keck School of Medicine, Los Angeles, USA.

OBJECTIVE This study was undertaken to investigate the role of the angiogenic factors vascular endothelial growth factor and basic fibroblast growth factor in the development and progression of Barrett esophagus and adenocarcinomas of the esophagus and gastroesophageal junction. METHODS Vascular endothelial growth factor and basic fibroblast growth factor messenger RNA expression levels, relative to the control gene encoding beta-actin, were measured by using a quantitative reverse transcription-polymerase chain reaction method (ABI 7700 Sequence Detector system) in specimens of Barrett intestinal metaplasia (n = 16), dysplasia (n = 11), adenocarcinoma (n = l 5), and matching normal squamous esophageal tissues (n = 35). Vascular endothelial growth factor and basic fibroblast growth factor protein expression and CD31(+) microvessel density were assessed by means of immunohistochemistry in 25 tissue sections that included representative areas for each of these Barrett stages. RESULTS Expression levels were significantly increased in adenocarcinoma compared with in either normal squamous mucosa (P <.0001 for both genes) or intestinal metaplasia (vascular endothelial growth factor, P =.002; basic fibroblast growth factor, P <.0001). Vascular endothelial growth factor levels were also significantly higher in cancer tissues compared with dysplasia tissues (P =.024, Mann-Whitney U test). Basic fibroblast growth factor expression was also significantly increased in Barrett dysplastic mucosa compared with in intestinal metaplasia or normal esophageal mucosa. Microvessel density was generally higher in adenocarcinoma compared with in preneoplastic Barrett tissues. The pattern of vascular endothelial growth factor and basic fibroblast growth factor protein expression was similar to the messenger RNA expression pattern, with the exception that mucin-containing goblet cells stained intensely for vascular endothelial growth factor and only weak vascular endothelial growth factor staining was present in some adenocarcinomas. CONCLUSIONS Vascular endothelial growth factor and basic fibroblast growth factor messenger RNA expression levels are significantly upregulated in esophageal and gastroesophageal junction adenocarcinomas, suggesting a role for these angiogenic factors in the development of these cancers. Vascular endothelial growth factor and basic fibroblast growth factor messenger RNA expression levels are also increased in some Barrett esophagus tissues, with this increase occurring at an earlier stage for basic fibroblast growth factor than for vascular endothelial growth factor. Basic fibroblast growth factor protein expression pattern is similar to the messenger RNA expression pattern, but unlike the messenger RNA findings, vascular endothelial growth factor protein expression is strongest in goblet cells.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008222 Lymphokines Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. Lymphocyte Mediators,Mediators, Lymphocyte
D008679 Metaplasia A condition in which there is a change of one adult cell type to another similar adult cell type.
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004938 Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. Cancer of Esophagus,Esophageal Cancer,Cancer of the Esophagus,Esophagus Cancer,Esophagus Neoplasm,Neoplasms, Esophageal,Cancer, Esophageal,Cancer, Esophagus,Cancers, Esophageal,Cancers, Esophagus,Esophageal Cancers,Esophageal Neoplasm,Esophagus Cancers,Esophagus Neoplasms,Neoplasm, Esophageal,Neoplasm, Esophagus,Neoplasms, Esophagus
D004943 Esophagogastric Junction The area covering the terminal portion of ESOPHAGUS and the beginning of STOMACH at the cardiac orifice. Gastroesophageal Junction,Gastroesophageal Junctions,Junction, Esophagogastric,Junction, Gastroesophageal,Junctions, Gastroesophageal
D004945 Esophagoscopy Endoscopic examination, therapy or surgery of the esophagus. Esophagoscopic Surgical Procedures,Surgical Procedures, Esophagoscopic,Esophagoscopic Surgery,Surgery, Esophagoscopic,Esophagoscopic Surgeries,Esophagoscopic Surgical Procedure,Esophagoscopies,Procedure, Esophagoscopic Surgical,Procedures, Esophagoscopic Surgical,Surgeries, Esophagoscopic,Surgical Procedure, Esophagoscopic
D004947 Esophagus The muscular membranous segment between the PHARYNX and the STOMACH in the UPPER GASTROINTESTINAL TRACT.

Related Publications

Reginald V N Lord, and Ji Min Park, and Kumari Wickramasinghe, and Steven R DeMeester, and Stefan Oberg, and Dennis Salonga, and Jon Singer, and Jeffrey H Peters, and Kathleen D Danenberg, and Tom R Demeester, and Peter V Danenberg
January 2001, Anticancer research,
Reginald V N Lord, and Ji Min Park, and Kumari Wickramasinghe, and Steven R DeMeester, and Stefan Oberg, and Dennis Salonga, and Jon Singer, and Jeffrey H Peters, and Kathleen D Danenberg, and Tom R Demeester, and Peter V Danenberg
November 1997, The Journal of thoracic and cardiovascular surgery,
Reginald V N Lord, and Ji Min Park, and Kumari Wickramasinghe, and Steven R DeMeester, and Stefan Oberg, and Dennis Salonga, and Jon Singer, and Jeffrey H Peters, and Kathleen D Danenberg, and Tom R Demeester, and Peter V Danenberg
January 2002, Oncology reports,
Reginald V N Lord, and Ji Min Park, and Kumari Wickramasinghe, and Steven R DeMeester, and Stefan Oberg, and Dennis Salonga, and Jon Singer, and Jeffrey H Peters, and Kathleen D Danenberg, and Tom R Demeester, and Peter V Danenberg
August 2004, Pathology international,
Reginald V N Lord, and Ji Min Park, and Kumari Wickramasinghe, and Steven R DeMeester, and Stefan Oberg, and Dennis Salonga, and Jon Singer, and Jeffrey H Peters, and Kathleen D Danenberg, and Tom R Demeester, and Peter V Danenberg
February 2000, The British journal of dermatology,
Reginald V N Lord, and Ji Min Park, and Kumari Wickramasinghe, and Steven R DeMeester, and Stefan Oberg, and Dennis Salonga, and Jon Singer, and Jeffrey H Peters, and Kathleen D Danenberg, and Tom R Demeester, and Peter V Danenberg
January 2015, International journal of clinical and experimental pathology,
Reginald V N Lord, and Ji Min Park, and Kumari Wickramasinghe, and Steven R DeMeester, and Stefan Oberg, and Dennis Salonga, and Jon Singer, and Jeffrey H Peters, and Kathleen D Danenberg, and Tom R Demeester, and Peter V Danenberg
October 2000, Analytical and quantitative cytology and histology,
Reginald V N Lord, and Ji Min Park, and Kumari Wickramasinghe, and Steven R DeMeester, and Stefan Oberg, and Dennis Salonga, and Jon Singer, and Jeffrey H Peters, and Kathleen D Danenberg, and Tom R Demeester, and Peter V Danenberg
June 2017, Hematology/oncology clinics of North America,
Reginald V N Lord, and Ji Min Park, and Kumari Wickramasinghe, and Steven R DeMeester, and Stefan Oberg, and Dennis Salonga, and Jon Singer, and Jeffrey H Peters, and Kathleen D Danenberg, and Tom R Demeester, and Peter V Danenberg
March 2009, Cancer letters,
Reginald V N Lord, and Ji Min Park, and Kumari Wickramasinghe, and Steven R DeMeester, and Stefan Oberg, and Dennis Salonga, and Jon Singer, and Jeffrey H Peters, and Kathleen D Danenberg, and Tom R Demeester, and Peter V Danenberg
December 2007, Molecular carcinogenesis,
Copied contents to your clipboard!